I-Mab Valuation Offers A Biotech Investment Opportunity

Jun. 23, 2022 5:27 PM ETI-Mab (IMAB) Stock, , , , , , , , , , , , , , 3 Comments
Chris Lacoursiere
369 Followers

Summary

  • The biotech indices have fallen considerably.
  • Many biotechs are trading with negative enterprise values despite unprecedented innovation in the biotech industry.
  • I-Mab is headed for commercialization with enough cash to carry them into 2025 with multiple products hitting the market.
  • I-Mab shares appear significantly undervalued.

Cancer cells on dna stand background. 3d illustration

Mohammed Haneefa Nizamudeen/iStock via Getty Images

I-Mab (NASDAQ:IMAB) shares are trading near cash and represent a value proposition. Over the past year, the biotech indices have seen their worst selloff ever. A speculative rally between 2020 - 2021 coupled with changing fiscal policies and a potential recession has caused many

This article was written by

369 Followers
Head of Investor Relations GoLogiq (OTCM: GOLQ) Registered Pharmacist, Investment with a focus on Emerging Markets E-commerce and Biotech. Focused on Deep Value and investing before the broader market. Urging investors to do due diligence and most important to know what they own.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About IMAB Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on IMAB

Related Stocks

SymbolLast Price% Chg
IMAB
--